{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T05:51:17Z","timestamp":1774763477644,"version":"3.50.1"},"reference-count":58,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T00:00:00Z","timestamp":1719014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy: Oncology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.omton.2024.200841","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T16:21:06Z","timestamp":1719246066000},"page":"200841","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["CD38 regulates chronic lymphocytic leukemia proliferation via CD45 phosphatase activity"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0809-3550","authenticated-orcid":false,"given":"John F.","family":"Imbery","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celina","family":"Wiik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Heinzelbecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny K.","family":"Jebsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mia K.","family":"Dobbing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nunzio","family":"Bottini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie M.","family":"Stanford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludvig A.","family":"Munthe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geir E.","family":"Tj\u00f8nnfjord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Tveita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Szodoray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Britt","family":"Nakken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2024.200841_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.omton.2024.200841_bib2","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.omton.2024.200841_bib3","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.cca.2018.04.026","article-title":"ZAP-70 in chronic lymphocytic leukemia: A meta-analysis","volume":"483","author":"Liu","year":"2018","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.omton.2024.200841_bib4","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2002-10-3306","article-title":"ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile","volume":"101","author":"Wiestner","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.omton.2024.200841_bib5","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.omton.2024.200841_bib6","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/10428190109097682","article-title":"CD38 expression correlates with adverse biological features and predicts poor clinical outcome in B-cell chronic lymphocytic leukemia","volume":"42","author":"D'Arena","year":"2001","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.omton.2024.200841_bib7","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1182\/blood.V98.9.2633","article-title":"Clinical significance of CD38 expression in chronic lymphocytic leukemia","volume":"98","author":"Del Poeta","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.omton.2024.200841_bib8","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1182\/blood-2007-04-083832","article-title":"CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells","volume":"110","author":"Damle","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.omton.2024.200841_bib9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.yexmp.2007.08.009","article-title":"Zap-70 and CD38 as predictors of IgVH mutation in CLL","volume":"83","author":"Cruse","year":"2007","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.omton.2024.200841_bib10","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1182\/blood.V99.3.1023","article-title":"CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease","volume":"99","author":"Hamblin","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.omton.2024.200841_bib11","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.3389\/fimmu.2019.01187","article-title":"The Multi-faceted Ecto-enzyme CD38: Roles in Immunomodulation, Cancer, Aging, and Metabolic Diseases","volume":"10","author":"Hogan","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2024.200841_bib12","doi-asserted-by":"crossref","first-page":"395","DOI":"10.4049\/jimmunol.160.1.395","article-title":"Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member","volume":"160","author":"Deaglio","year":"1998","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omton.2024.200841_bib13","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1182\/blood-2003-03-0989","article-title":"CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells","volume":"102","author":"Deaglio","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.omton.2024.200841_bib14","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/leu.2014.207","article-title":"The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting","volume":"29","author":"Vaisitti","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2024.200841_bib15","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/leu.2010.36","article-title":"CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells","volume":"24","author":"Vaisitti","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2024.200841_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169159","article-title":"Spleen Tyrosine Kinase Is Involved in the CD38 Signal Transduction Pathway in Chronic Lymphocytic Leukemia","volume":"11","author":"Benkisser-Petersen","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.omton.2024.200841_bib17","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.it.2013.07.002","article-title":"B cell receptor signaling in chronic lymphocytic leukemia","volume":"34","author":"Burger","year":"2013","journal-title":"Trends Immunol."},{"key":"10.1016\/j.omton.2024.200841_bib18","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omton.2024.200841_bib19","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1600-065X.2008.00752.x","article-title":"CD45, CD148, and Lyp\/Pep: critical phosphatases regulating Src family kinase signaling networks in immune cells","volume":"228","author":"Hermiston","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.omton.2024.200841_bib20","doi-asserted-by":"crossref","first-page":"E3","DOI":"10.1073\/pnas.1117374108","article-title":"Quantitative differences in CD45 expression unmask functions for CD45 in B-cell development, tolerance, and survival","volume":"109","author":"Zikherman","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2024.200841_bib21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1182\/asheducation-2011.1.96","article-title":"Nurture versus nature: the microenvironment in chronic lymphocytic leukemia","volume":"2011","author":"Burger","year":"2011","journal-title":"Hematology. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.omton.2024.200841_bib22","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1046\/j.1365-2141.2003.04679.x","article-title":"Role of the microenvironment in chronic lymphocytic leukaemia","volume":"123","author":"Caligaris-Cappio","year":"2003","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omton.2024.200841_bib23","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.celrep.2013.07.011","article-title":"Chronic lymphocytic leukemia cells are activated and proliferate in response to specific T helper cells","volume":"4","author":"Os","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.omton.2024.200841_bib24","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/bjh.18285","article-title":"T-helper cell regulation of CD45 phosphatase activity by galectin-1 and CD43 governs chronic lymphocytic leukaemia proliferation","volume":"198","author":"Imbery","year":"2022","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omton.2024.200841_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109525","article-title":"Integration of T helper and BCR signals governs enhanced plasma cell differentiation of memory B cells by regulation of CD45 phosphatase activity","volume":"36","author":"Szodoray","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.omton.2024.200841_bib26","doi-asserted-by":"crossref","first-page":"827","DOI":"10.4049\/jimmunol.1401350","article-title":"Chronic lymphocytic leukemia cells express CD38 in response to Th1 cell-derived IFN-gamma by a T-bet-dependent mechanism","volume":"194","author":"Burgler","year":"2015","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omton.2024.200841_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111006","article-title":"Tetraspanin CD53 controls T\u00a0cell immunity through regulation of CD45RO stability, mobility, and function","volume":"39","author":"Dunlock","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.omton.2024.200841_bib28","doi-asserted-by":"crossref","first-page":"13972","DOI":"10.1073\/pnas.1205028109","article-title":"High-throughput screen using a single-cell tyrosine phosphatase assay reveals biologically active inhibitors of tyrosine phosphatase CD45","volume":"109","author":"Stanford","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2024.200841_bib29","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jaci.2016.01.035","article-title":"T-helper signals restore B-cell receptor signaling in autoreactive anergic B cells by upregulating CD45 phosphatase activity","volume":"138","author":"Szodoray","year":"2016","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"key":"10.1016\/j.omton.2024.200841_bib30","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1021\/jm502009h","article-title":"Discovery, Synthesis, and Biological Evaluation of Thiazoloquin(az)olin(on)es as Potent CD38 Inhibitors","volume":"58","author":"Haffner","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.omton.2024.200841_bib31","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.cmet.2018.03.016","article-title":"A Potent and Specific CD38 Inhibitor Ameliorates Age-Related Metabolic Dysfunction by Reversing Tissue NAD(+) Decline","volume":"27","author":"Tarrago","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.omton.2024.200841_bib32","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood.V124.21.3474.3474","article-title":"Direct in\u00a0Vitro Comparison of Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and Ab79","volume":"124","author":"Lammerts van Bueren","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.omton.2024.200841_bib33","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0145-2126(98)00154-4","article-title":"MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation","volume":"23","author":"Stacchini","year":"1999","journal-title":"Leuk. Res."},{"key":"10.1016\/j.omton.2024.200841_bib34","article-title":"Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia Cell Line","volume":"10","author":"Agathangelidis","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.omton.2024.200841_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076607","article-title":"Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in\u00a0vitro and in\u00a0vivo studies relevant to disease","volume":"8","author":"Hertlein","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.omton.2024.200841_bib36","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.leukres.2015.10.008","article-title":"Isolation of a novel chronic lymphocytic leukemic (CLL) cell line and development of an in\u00a0vivo mouse model of CLL","volume":"40","author":"Kellner","year":"2016","journal-title":"Leuk. Res."},{"key":"10.1016\/j.omton.2024.200841_bib37","doi-asserted-by":"crossref","first-page":"71981","DOI":"10.18632\/oncotarget.18234","article-title":"Cell lines generated from a chronic lymphocytic leukemia mouse model exhibit constitutive Btk and Akt signaling","volume":"8","author":"Singh","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.omton.2024.200841_bib38","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1007\/s00259-018-3941-3","article-title":"ImmunoPET imaging of CD38 in murine lymphoma models using (89)Zr-labeled daratumumab","volume":"45","author":"Kang","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.omton.2024.200841_bib39","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1158\/1078-0432.CCR-18-3412","article-title":"Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia","volume":"25","author":"Manna","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2024.200841_bib40","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20220201","article-title":"Human CD38 regulates B cell antigen receptor dynamic organization in normal and malignant B cells","volume":"219","author":"Camponeschi","year":"2022","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.omton.2024.200841_bib41","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1182\/blood-2002-11-3456","article-title":"Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations","volume":"101","author":"Camacho","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.omton.2024.200841_bib42","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/hon.2904","article-title":"CD38 expression is an important prognostic marker in diffuse large B-cell lymphoma","volume":"39","author":"Wada","year":"2021","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.omton.2024.200841_bib43","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.leukres.2015.12.015","article-title":"CD38+ CD58- is an independent adverse prognostic factor in paediatric Philadelphia chromosome negative B cell acute lymphoblastic leukaemia patients","volume":"43","author":"Li","year":"2016","journal-title":"Leuk. Res."},{"key":"10.1016\/j.omton.2024.200841_bib44","first-page":"1234","article-title":"The phenotype of normal, reactive and malignant plasma cells. Identification of \"many and multiple myelomas\" and of new targets for myeloma therapy","volume":"91","author":"Bataille","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.omton.2024.200841_bib45","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.omton.2024.200841_bib46","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omton.2024.200841_bib47","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.omton.2024.200841_bib48","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1158\/1078-0432.CCR-15-2095","article-title":"The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia","volume":"23","author":"Matas-Cespedes","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2024.200841_bib49","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omton.2024.200841_bib50","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"mAbs"},{"key":"10.1016\/j.omton.2024.200841_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17091566","article-title":"The Role of Galectin-1 in Cancer Progression, and Synthetic Multivalent Systems for the Study of Galectin-1","volume":"17","author":"Cousin","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omton.2024.200841_bib52","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1042\/BST0361472","article-title":"Galectin-glycan lattices regulate cell-surface glycoprotein organization and signalling","volume":"36","author":"Garner","year":"2008","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.omton.2024.200841_bib53","doi-asserted-by":"crossref","first-page":"170","DOI":"10.22203\/eCM.v023a13","article-title":"Multivalent structure of galectin-1-nanogold complex serves as potential therapeutics for rheumatoid arthritis by enhancing receptor clustering","volume":"23","author":"Huang","year":"2012","journal-title":"Eur. Cell. Mater."},{"key":"10.1016\/j.omton.2024.200841_bib54","doi-asserted-by":"crossref","first-page":"26860","DOI":"10.1074\/jbc.M109.037507","article-title":"Galectin-1 co-clusters CD43\/CD45 on dendritic cells and induces cell activation and migration through Syk and protein kinase C signaling","volume":"284","author":"Fulcher","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omton.2024.200841_bib55","doi-asserted-by":"crossref","first-page":"230","DOI":"10.2144\/000114610","article-title":"Protocol for adhesion and immunostaining of lymphocytes and other non-adherent cells in culture","volume":"63","author":"Tsang","year":"2017","journal-title":"Biotechniques"},{"key":"10.1016\/j.omton.2024.200841_bib56","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.omton.2024.200841_bib57","doi-asserted-by":"crossref","first-page":"67175","DOI":"10.18632\/oncotarget.11946","article-title":"Tumor-specific CD4+ T\u00a0cells eradicate myeloma cells genetically deficient in MHC class II display","volume":"7","author":"Tveita","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.omton.2024.200841_bib58","doi-asserted-by":"crossref","first-page":"W171","DOI":"10.1093\/nar\/gkz365","article-title":"CHOPCHOP v3: expanding the CRISPR web toolbox beyond genome editing","volume":"47","author":"Labun","year":"2019","journal-title":"Nucleic Acids Res."}],"container-title":["Molecular Therapy: Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329924000833?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329924000833?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T11:59:32Z","timestamp":1726833572000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329924000833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2950329924000833"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2024.200841","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD38 regulates chronic lymphocytic leukemia proliferation via CD45 phosphatase activity","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy: Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2024.200841","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"200841"}}